ID   SRXN1_HUMAN             Reviewed;         137 AA.
AC   Q9BYN0; B2R543; Q8NDM3; Q96AK6;
DT   30-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   30-APR-2003, sequence version 2.
DT   07-APR-2021, entry version 160.
DE   RecName: Full=Sulfiredoxin-1;
DE            EC=1.8.98.2;
GN   Name=SRXN1; Synonyms=C20orf139, SRX, SRX1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Mammary cancer;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney, Lung, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15448164; DOI=10.1074/jbc.m409482200;
RA   Chang T.-S., Jeong W., Woo H.A., Lee S.M., Park S., Rhee S.G.;
RT   "Characterization of mammalian sulfiredoxin and its reactivation of
RT   hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in
RT   the active site to cysteine.";
RL   J. Biol. Chem. 279:50994-51001(2004).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF CYS-99.
RX   PubMed=15590625; DOI=10.1074/jbc.c400496200;
RA   Woo H.A., Jeong W., Chang T.-S., Park K.J., Park S.J., Yang J.S.,
RA   Rhee S.G.;
RT   "Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys
RT   peroxiredoxins.";
RL   J. Biol. Chem. 280:3125-3128(2005).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-32, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-11 AND ARG-16, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [11]
RP   STRUCTURE BY NMR OF 17-137.
RA   Gruschus J.M., Lee D.Y., Ferretti J.A., Rhee S.G.;
RT   "Solution structure of human sulfiredoxin (SRX).";
RL   Submitted (FEB-2004) to the PDB data bank.
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 32-137.
RX   PubMed=15952770; DOI=10.1021/bi050131i;
RA   Jonsson T.J., Murray M.S., Johnson L.C., Poole L.B., Lowther W.T.;
RT   "Structural basis for the retroreduction of inactivated peroxiredoxins by
RT   human sulfiredoxin.";
RL   Biochemistry 44:8634-8642(2005).
CC   -!- FUNCTION: Contributes to oxidative stress resistance by reducing
CC       cysteine-sulfinic acid formed under exposure to oxidants in the
CC       peroxiredoxins PRDX1, PRDX2, PRDX3 and PRDX4. Does not act on PRDX5 or
CC       PRDX6. May catalyze the reduction in a multi-step process by acting
CC       both as a specific phosphotransferase and a thioltransferase.
CC       {ECO:0000269|PubMed:15448164, ECO:0000269|PubMed:15590625}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[peroxiredoxin]-S-hydroxy-S-oxy-L-cysteine + [protein]-dithiol
CC         + ATP = [peroxiredoxin]-S-hydroxy-L-cysteine + [protein]-disulfide +
CC         ADP + H(+) + phosphate; Xref=Rhea:RHEA:17545, Rhea:RHEA-COMP:10593,
CC         Rhea:RHEA-COMP:10594, Rhea:RHEA-COMP:13681, Rhea:RHEA-COMP:14051,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29950, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:50058, ChEBI:CHEBI:61967,
CC         ChEBI:CHEBI:61973, ChEBI:CHEBI:456216; EC=1.8.98.2;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- INTERACTION:
CC       Q9BYN0; Q06830: PRDX1; NbExp=3; IntAct=EBI-15678820, EBI-353193;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15448164}.
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in kidney,
CC       lung, spleen and thymus. {ECO:0000269|PubMed:15448164}.
CC   -!- SIMILARITY: Belongs to the sulfiredoxin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SRXN1ID52295ch20p13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK312054; BAG34990.1; -; mRNA.
DR   EMBL; AL833944; CAD38799.1; -; mRNA.
DR   EMBL; AL121758; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC017001; AAH17001.1; -; mRNA.
DR   EMBL; BC032604; AAH32604.1; -; mRNA.
DR   EMBL; BC047707; AAH47707.1; -; mRNA.
DR   CCDS; CCDS13005.1; -.
DR   RefSeq; NP_542763.1; NM_080725.2.
DR   PDB; 1XW3; X-ray; 1.65 A; A=32-137.
DR   PDB; 1XW4; X-ray; 2.00 A; X=32-137.
DR   PDB; 1YZS; NMR; -; A=17-137.
DR   PDB; 2B6F; NMR; -; A=17-137.
DR   PDB; 2RII; X-ray; 2.60 A; X/Y=32-137.
DR   PDB; 3CYI; X-ray; 1.80 A; A=32-137.
DR   PDB; 3HY2; X-ray; 2.10 A; X/Y=32-137.
DR   PDBsum; 1XW3; -.
DR   PDBsum; 1XW4; -.
DR   PDBsum; 1YZS; -.
DR   PDBsum; 2B6F; -.
DR   PDBsum; 2RII; -.
DR   PDBsum; 3CYI; -.
DR   PDBsum; 3HY2; -.
DR   BMRB; Q9BYN0; -.
DR   SMR; Q9BYN0; -.
DR   BioGRID; 126716; 41.
DR   CORUM; Q9BYN0; -.
DR   DIP; DIP-59836N; -.
DR   IntAct; Q9BYN0; 2.
DR   STRING; 9606.ENSP00000371388; -.
DR   iPTMnet; Q9BYN0; -.
DR   PhosphoSitePlus; Q9BYN0; -.
DR   BioMuta; SRXN1; -.
DR   DMDM; 30315944; -.
DR   EPD; Q9BYN0; -.
DR   jPOST; Q9BYN0; -.
DR   MassIVE; Q9BYN0; -.
DR   MaxQB; Q9BYN0; -.
DR   PaxDb; Q9BYN0; -.
DR   PeptideAtlas; Q9BYN0; -.
DR   PRIDE; Q9BYN0; -.
DR   ProteomicsDB; 79670; -.
DR   Antibodypedia; 69340; 92 antibodies.
DR   DNASU; 140809; -.
DR   Ensembl; ENST00000381962; ENSP00000371388; ENSG00000271303.
DR   GeneID; 140809; -.
DR   KEGG; hsa:140809; -.
DR   UCSC; uc002wea.5; human.
DR   CTD; 140809; -.
DR   DisGeNET; 140809; -.
DR   GeneCards; SRXN1; -.
DR   HGNC; HGNC:16132; SRXN1.
DR   HPA; ENSG00000271303; Low tissue specificity.
DR   MIM; 617583; gene.
DR   neXtProt; NX_Q9BYN0; -.
DR   OpenTargets; ENSG00000271303; -.
DR   PharmGKB; PA25681; -.
DR   VEuPathDB; HostDB:ENSG00000271303.1; -.
DR   eggNOG; KOG3388; Eukaryota.
DR   GeneTree; ENSGT00390000007832; -.
DR   HOGENOM; CLU_124532_1_0_1; -.
DR   InParanoid; Q9BYN0; -.
DR   OMA; CHRFAAY; -.
DR   OrthoDB; 1421270at2759; -.
DR   PhylomeDB; Q9BYN0; -.
DR   TreeFam; TF300230; -.
DR   BRENDA; 1.8.98.2; 2681.
DR   PathwayCommons; Q9BYN0; -.
DR   BioGRID-ORCS; 140809; 10 hits in 995 CRISPR screens.
DR   ChiTaRS; SRXN1; human.
DR   EvolutionaryTrace; Q9BYN0; -.
DR   GeneWiki; SRXN1; -.
DR   GenomeRNAi; 140809; -.
DR   Pharos; Q9BYN0; Tbio.
DR   PRO; PR:Q9BYN0; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; Q9BYN0; protein.
DR   Bgee; ENSG00000271303; Expressed in islet of Langerhans and 113 other tissues.
DR   Genevisible; Q9BYN0; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016667; F:oxidoreductase activity, acting on a sulfur group of donors; IDA:UniProtKB.
DR   GO; GO:0032542; F:sulfiredoxin activity; IBA:GO_Central.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IBA:GO_Central.
DR   GO; GO:0006979; P:response to oxidative stress; IDA:UniProtKB.
DR   InterPro; IPR003115; ParB/Sulfiredoxin_dom.
DR   InterPro; IPR036086; ParB/Sulfiredoxin_sf.
DR   InterPro; IPR016692; Sulfiredoxin.
DR   PANTHER; PTHR21348; PTHR21348; 1.
DR   Pfam; PF02195; ParBc; 1.
DR   PIRSF; PIRSF017267; Sulfiredoxin; 1.
DR   SMART; SM00470; ParB; 1.
DR   SUPFAM; SSF110849; SSF110849; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antioxidant; ATP-binding; Cytoplasm; Disulfide bond;
KW   Magnesium; Methylation; Nucleotide-binding; Oxidoreductase; Phosphoprotein;
KW   Reference proteome.
FT   CHAIN           1..137
FT                   /note="Sulfiredoxin-1"
FT                   /id="PRO_0000211431"
FT   NP_BIND         98..101
FT                   /note="ATP"
FT   MOD_RES         11
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         16
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         32
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   DISULFID        99
FT                   /note="Interchain"
FT                   /evidence="ECO:0000250"
FT   MUTAGEN         99
FT                   /note="C->S: No effect on association with PRDX1, PRDX2,
FT                   PRDX3 or PRDX4."
FT                   /evidence="ECO:0000269|PubMed:15590625"
FT   STRAND          22..24
FT                   /evidence="ECO:0007744|PDB:1YZS"
FT   STRAND          26..28
FT                   /evidence="ECO:0007744|PDB:1YZS"
FT   STRAND          39..45
FT                   /evidence="ECO:0007744|PDB:1XW3"
FT   HELIX           46..48
FT                   /evidence="ECO:0007744|PDB:1XW3"
FT   HELIX           59..71
FT                   /evidence="ECO:0007744|PDB:1XW3"
FT   HELIX           73..75
FT                   /evidence="ECO:0007744|PDB:1XW3"
FT   STRAND          79..85
FT                   /evidence="ECO:0007744|PDB:1XW3"
FT   STRAND          91..94
FT                   /evidence="ECO:0007744|PDB:1XW3"
FT   HELIX           99..107
FT                   /evidence="ECO:0007744|PDB:1XW3"
FT   STRAND          111..120
FT                   /evidence="ECO:0007744|PDB:1XW3"
FT   HELIX           122..129
FT                   /evidence="ECO:0007744|PDB:1XW3"
FT   HELIX           130..132
FT                   /evidence="ECO:0007744|PDB:1XW3"
SQ   SEQUENCE   137 AA;  14259 MW;  44F2C4256E5574D0 CRC64;
     MGLRAGGTLG RAGAGRGAPE GPGPSGGAQG GSIHSGRIAA VHNVPLSVLI RPLPSVLDPA
     KVQSLVDTIR EDPDSVPPID VLWIKGAQGG DYFYSFGGCH RYAAYQQLQR ETIPAKLVQS
     TLSDLRVYLG ASTPDLQ
//
